Information Provided By: 
Fly News Breaks for December 19, 2016
BCR
Dec 19, 2016 | 07:51 EDT
Wells Fargo predicts that data due to be presented on January 25 on C.R. Bard's Lutonix drug-coated balloon will be positive. The firm bases its opinion on "earlier smaller studies" and what it sees as "the relatively low efficacy" of the current standard of care. Wells estimates that the total addressable market for the product is $720M in the U.S. alone. It keeps an Outperform rating on C.R. Bard.
News For BCR From the Last 2 Days
There are no results for your query BCR
